Cingulate Inc. Profile Avatar - Palmy Investing

Cingulate Inc.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is …

Biotechnology
US, Kansas City [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Cingulate Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Cingulate Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Cingulate Inc..

End of CING's Analysis
CIK: 1862150 CUSIP: 17248W105 ISIN: US17248W2044 LEI: - UEI: -
Secondary Listings
CING has no secondary listings inside our databases.